Joseph E Tomaszewski
Overview
Explore the profile of Joseph E Tomaszewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1671
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Navas T, Pfister T, Colantonio S, Aziz A, Dieckman L, Saul R, et al.
PLoS One
. 2018 Jun;
13(6):e0199361.
PMID: 29928062
The presence of cancer stem cells (CSCs) and the induction of epithelial-to-mesenchymal transition (EMT) in tumors are associated with tumor aggressiveness, metastasis, drug resistance, and poor prognosis, necessitating the development...
2.
Balasubramanian P, Kinders R, Kummar S, Gupta V, Hasegawa D, Menachery A, et al.
PLoS One
. 2017 Apr;
12(4):e0175414.
PMID: 28403214
Circulating tumor cells (CTCs) are increasingly employed for research and clinical monitoring of cancer, though most current methods do not permit the isolation of non-epithelial tumor cells. Furthermore, CTCs isolated...
3.
Ji J, Zhang Y, Redon C, Reinhold W, Chen A, Fogli L, et al.
PLoS One
. 2017 Feb;
12(2):e0171582.
PMID: 28158293
Phosphorylated H2AX (γ-H2AX) is a sensitive marker for DNA double-strand breaks (DSBs), but the variability of H2AX expression in different cell and tissue types makes it difficult to interpret the...
4.
Avtanski D, Nagalingam A, Tomaszewski J, Risbood P, Difillippantonio M, Saxena N, et al.
Mol Oncol
. 2016 Jun;
10(7):1118-32.
PMID: 27259808
The tumor suppressor p53 plays a critical role in suppressing cancer growth and progression and is an attractive target for the development of new targeted therapies. We synthesized several indolo-pyrido-isoquinolin...
5.
Srivastava A, Hollingshead M, Weiner J, Navas T, Evrard Y, Khin S, et al.
Clin Cancer Res
. 2016 Mar;
22(14):3683-94.
PMID: 27001313
Purpose: Rational development of targeted MET inhibitors for cancer treatment requires a quantitative understanding of target pharmacodynamics, including molecular target engagement, mechanism of action, and duration of effect. Experimental Design:...
6.
Srivastava A, Jaganathan S, Stephen L, Hollingshead M, Layhee A, Damour E, et al.
Clin Cancer Res
. 2015 Oct;
22(4):1000-10.
PMID: 26446940
Purpose: To support clinical pharmacodynamic evaluation of the Smac mimetic TL32711 (birinapant) and other apoptosis-targeting drugs, we describe the development, validation, and application of novel immunoassays for 15 cytosolic and...
7.
Teicher B, Tomaszewski J
Biochem Pharmacol
. 2015 May;
96(1):1-9.
PMID: 25935605
Proteasome inhibitors have a 20 year history in cancer therapy. The first proteasome inhibitor, bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment, moved rapidly through development from bench in 1994...
8.
Nguyen D, Rubinstein L, Takebe N, Miele L, Tomaszewski J, Ivy P, et al.
J Hematol Oncol
. 2015 Feb;
8:9.
PMID: 25653136
Background: Notch1 transmembrane receptor is activated through ligand-binding- triggered proteolytic cleavages and, upon release, the intracellular domain (N1-ICD) translocates into the nucleus and modulates target gene transcriptions. Notch activation has...
9.
Park S, Kinders R, Khin S, Hollingshead M, Antony S, Parchment R, et al.
Anal Biochem
. 2014 May;
459:1-11.
PMID: 24799347
Hypoxia-inducible factor-1 alpha (HIF-1α) is an important marker of hypoxia in human tumors and has been implicated in tumor progression. Drugs targeting HIF-1α are being developed, but the ability to...
10.
DeMichele A, Berry D, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski J, et al.
Clin Cancer Res
. 2013 Mar;
19(11):2817-23.
PMID: 23470967
New approaches to drug development are critically needed to lessen the time, cost, and resources necessary to identify and optimize active agents. Strategies to accelerate drug development include testing drugs...